Results 241 to 250 of about 797,541 (308)

Evaluation of cardiac histology and cell death markers during the progression of diabetes in a streptozotocin‐induced diabetes rat model

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Daily insulin administration in streptozotocin‐induced diabetic rats prevented cardiac damage associated with diabetic cardiomyopathy, including hypertrophy, fibrosis, and expression of cell death markers, at 12 weeks. However, cyclophilin D, a marker of mitochondrial permeability transition pore‐opening‐associated cell death (necrosis), was observed ...
Tamara Sáez   +5 more
wiley   +1 more source

Early diabetes‐like phenotypes in germ‐free mice induced by gut microbiota from patients with type 2 diabetes

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Gut microbiota from patients with type 2 diabetes induced early diabetes‐like phenotypes in germ‐free mice, including progressive glucose intolerance and mild renal injury. Longitudinal profiling revealed persistent dysbiosis preceding stable metabolic dysfunction, with coordinated fecal and plasma metabolite alterations and a prominent L‐Dopa ...
Jianghao Feng   +6 more
wiley   +1 more source

Animal models in molecular biology research: Challenges, ethical imperatives, and the path to human‐relevant translation

open access: yesAnimal Models and Experimental Medicine, EarlyView.
The graphical abstract shows how molecular biology research has shifted from using traditional animal models toward using methods that are more relevant to humans. It points out the main problems, differences between species, difficulty in reproducing results, moral issues, and lack of infrastructure that make translational accuracy harder to achieve ...
Md. Shajid Hossain Rafi   +6 more
wiley   +1 more source

Hematoma Interleukin‐1 Receptor Antagonist Concentrations Predict Long‐Term Outcome in Acute Human Intracerebral Hemorrhage

open access: yesAnnals of Neurology, EarlyView.
Objectives The interleukin (IL)‐1, IL‐6, and C‐reactive protein (CRP) pathway is central to the immune response after intracerebral hemorrhage (ICH). We tested for associations between hematoma and plasma cytokine concentrations and patient outcomes in Minimally Invasive Surgery Plus Rt‐PA for ICH Evacuation Phase III (MISTIE III) participants ...
Adrian R. Parry‐Jones   +54 more
wiley   +1 more source

Gut–Brain Axis Modulation by Short‐Chain Fatty Acids Exerts Disease‐Modifying Effects in a Murine Model of Drug‐Resistant Epilepsy

open access: yesAnnals of Neurology, EarlyView.
Objective Drug‐resistant epilepsy (DRE) remains a clinical challenge, as therapies modifying disease trajectory are lacking. Increasing evidence implicates gut microbiota dysbiosis in epilepsy pathophysiology, with short‐chain fatty acids (SCFAs) emerging as key microbial metabolites with neuroprotective and anti‐inflammatory properties.
Akash A. Bera   +16 more
wiley   +1 more source

Hyperacute Interleukin‐1β Production and Neutrophil Extracellular Trap Formation in the Cerebral Circulation of Stroke Patients with Large Vessel Occlusion

open access: yesAnnals of Neurology, EarlyView.
Acute ischemic stroke due to large vessel occlusion is associated with rapid intravascular immune activation. Analysis of arterial blood sampled distal to the thrombus during mechanical thrombectomy revealed increased extracellular adenosine triphosphate (ATP) and interleukin‐1β (IL‐1β) levels, evidence of inflammasome priming in monocytes, and ...
Justine Münsterberg   +33 more
wiley   +1 more source

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

open access: yesAnnals of Neurology, EarlyView.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy